Zai launches Optune in Hong Kong for GBM

Zai Lab Ltd. (NASDAQ:ZLAB) said Friday it launched glioblastoma multiforme treatment Optune in Hong Kong, a territory it regards as strategic as it plans to seek the therapy’s approval in mainland China.

Optune uses Tumor Treating Fields technology, in which electrodes deliver alternating electric fields to disrupt the division of cancer cells in the brain. Zai’s partner Novocure Ltd. (NASDAQ:NVCR) markets Optune in the U.S., select European countries, Israel and Japan...